表1.
HAPR组和No-HAPR组的临床基线资料
Baseline characteristics of the patients in HAPR and No-HAPR groups
| Variables | HAPR(n=31) | No-HAPR(n=93) | P |
| HAPR, high on aspirin platelet reactivity; BMI, body mass index; ACEI, angiotensin converse enzyme inhibitor；ARB, angiotensin receptor inhibitor；CCB, calcium channel blocker. *P < 0.05. | |||
| Age/years, x±s | 76.3±7.3 | 74.8±8.9 | 0.063 |
| Male，n(%) | 27(87.1) | 72(77.4) | 0.308 |
| BMI/(kg/m2), x±s | 26.1±3.3 | 24.5±3.1 | 0.451 |
| Hypertension，n(%) | 25(80.6) | 66(71.0) | 0.354 |
| Diabetes，n(%) | 12(38.7) | 32(34.4) | 0.670 |
| Current smoking，n(%) | 11(35.5) | 15(16.1) | 0.039* |
| Hyperlipidemia，n(%) | 27(87.1) | 75(80.6) | 0.589 |
| Essential medicines，n(%) | 14(45.2) | 55(59.1) | 0.212 |
| ACEI/ARB | 22(70.9) | 61(65.6) | 0.663 |
| β-blocker | 12(38.7) | 45(48.4) | 0.408 |
| CCB | 13(41.9) | 31(33.3) | 0.395 |
| Nitrates | 24(77.4) | 81(87.1) | 0.249 |
| Stains | 27(87.1) | 72(77.4) | 0.308 |
| Cardiovascular events，n(%) | 8 (25.8) | 9 (9.7) | 0.037 |